Russell Skibsted

CIK: 0001308105

Transaction Breakdown

Open Market Buys (P)7 (63.6%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)4 (36.4%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

PCSA

Processa Pharmaceuticals, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (11 total)

PCSA
Processa Pharmaceuticals, Inc.
Jul 26, 2026
Award(A)
Restricted Stock Units
Direct
11.9K shares-
PCSA
Processa Pharmaceuticals, Inc.
Jun 30, 2026
Purchase(P)
Direct
3.3K shares at avg. $1.93$6K
PCSA
Processa Pharmaceuticals, Inc.
Jun 15, 2026
Purchase(P)
Direct
2.7K shares at avg. $2.22$6K
PCSA
Processa Pharmaceuticals, Inc.
May 29, 2026
Purchase(P)
Direct
2.3K shares at avg. $2.57$6K
PCSA
Processa Pharmaceuticals, Inc.
May 15, 2026
Purchase(P)
Direct
2K shares at avg. $2.97$6K
PCSA
Processa Pharmaceuticals, Inc.
Apr 30, 2026
Purchase(P)
Direct
2.2K shares at avg. $2.69$6K
PCSA
Processa Pharmaceuticals, Inc.
Apr 15, 2026
Purchase(P)
Direct
2K shares at avg. $2.97$6K
PCSA
Processa Pharmaceuticals, Inc.
Mar 31, 2026
Purchase(P)
Direct
2.3K shares at avg. $2.54$6K
PCSA
Processa Pharmaceuticals, Inc.
Oct 1, 2025
Award(A)
Stock Options (Right to Buy)
Direct
324K shares-
PCSA
Processa Pharmaceuticals, Inc.
Oct 1, 2025
Award(A)
Restricted Stock Units
Direct
108K shares-
PCSA
Processa Pharmaceuticals, Inc.
Jul 24, 2025
Award(A)
Restricted Stock Units
Direct
1.8M shares-

		Type	Shares	Price		Ownership
Jul 26, 2026	PCSA Processa Pharmaceuticals, Inc.	Award(A) Restricted Stock Units	11,883	-	-	Direct
Jun 30, 2026	PCSA Processa Pharmaceuticals, Inc.	Purchase(P)	3,277	$1.93	$6,325	Direct
Jun 15, 2026	PCSA Processa Pharmaceuticals, Inc.	Purchase(P)	2,654	$2.22	$5,892	Direct
May 29, 2026	PCSA Processa Pharmaceuticals, Inc.	Purchase(P)	2,292	$2.57	$5,890	Direct
May 15, 2026	PCSA Processa Pharmaceuticals, Inc.	Purchase(P)	1,984	$2.97	$5,892	Direct
Apr 30, 2026	PCSA Processa Pharmaceuticals, Inc.	Purchase(P)	2,190	$2.69	$5,891	Direct
Apr 15, 2026	PCSA Processa Pharmaceuticals, Inc.	Purchase(P)	1,984	$2.97	$5,892	Direct
Mar 31, 2026	PCSA Processa Pharmaceuticals, Inc.	Purchase(P)	2,324	$2.54	$5,891	Direct
Oct 1, 2025	PCSA Processa Pharmaceuticals, Inc.	Award(A) Stock Options (Right to Buy)	324,000	-	-	Direct
Oct 1, 2025	PCSA Processa Pharmaceuticals, Inc.	Award(A) Restricted Stock Units	108,000	-	-	Direct
Jul 24, 2025	PCSA Processa Pharmaceuticals, Inc.	Award(A) Restricted Stock Units	1,775,044	-	-	Direct

1-11 of 11 transactions

About SKIBSTED RUSSELL

SKIBSTED RUSSELL (SEC CIK 0001308105) files insider reports with the SEC as Chief Financial Officer of Processa Pharmaceuticals, Inc. (PCSA).

Signal8 holds 11 ownership filings by SKIBSTED RUSSELL, all Form 4s, filed between Jul 28, 2025 and Jul 28, 2026. Those filings report 11 transactions, from Jul 24, 2025 to Jul 26, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on SKIBSTED RUSSELL's filings is in VERO BEACH, FL.

Recent filings by SKIBSTED RUSSELL

Jul 26, 2026: Grant or award of PCSA derivative securities (Form 4, code A).
Jun 30, 2026: Open-market purchase of PCSA shares (Form 4, code P).
Jun 15, 2026: Open-market purchase of PCSA shares (Form 4, code P).
May 29, 2026: Open-market purchase of PCSA shares (Form 4, code P).
May 15, 2026: Open-market purchase of PCSA shares (Form 4, code P).

Other insiders filing for Processa Pharmaceuticals, Inc. (PCSA)

Ng George K, Chief Executive Officer
GUJRATHI SHEILA, Director
Yorke Justin W, Director
Pannu Geraldine, Director
Neal James R, Director
Lin Patrick, Chief Business - Strategy Off

How to read Form 4 transaction codes